1. Patients with depressive, anxiety, and obsessive-compulsive and related disorders 2. Healthy Controls
Conditions
Interventions
None listed
Sponsors
Keio University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: For Patients: 1. Individuals aged 18 years or older diagnosed with any of the following according to DSM-5-TR criteria: depressive disorders, anxiety disorders, or obsessive-compulsive and related disorders accompanied by rumination or obsessions. 2. Individuals currently undergoing Cognitive Behavioral Therapy (CBT) focused on rumination or Exposure and Response Prevention (ERP) with a therapist, or performing these as structured homework assignments. 3. Individuals judged by their primary physician to have the capacity to provide informed consent. For Healthy Controls: 1. Individuals with no history of psychiatric disorders who volunteered for the study via the recruitment website. 2. Individuals aged 18 years or older at the time of providing informed consent.
Exclusion criteria
Exclusion criteria: For Patients: 1. Individuals with physical conditions that interfere with EEG electrode placement or measurement (e.g., scalp dermatosis, cranial bone defects) 2. Individuals with neuropsychiatric (e.g., epilepsy, substance use disorders, organic brain disorders) or medical conditions (e.g. brain tumors, cerebral infarction, impaired consciousness, or traumatic brain injury) known to significantly affect EEG signals 3. Individuals currently undergoing treatments expected to significantly alter EEG results (e.g., Electroconvulsive Therapy [ECT], Transcranial Magnetic Stimulation [TMS], or use of anti-epileptic medications) 4. Individuals with severe suicidal ideation 5. Individuals whose primary diagnosis is a neuropsychiatric disorder other than those targeted in this study (e.g., schizophrenia) 6. Any other individuals determined by the principal investigator or sub-investigator to be unsuitable for the study For Healthy Controls: 1. Individuals with physical conditions that interfere with EEG electrode placement or measurement (e.g., scalp dermatosis, cranial bone defects) 2. Individuals with neuropsychiatric (e.g., epilepsy, substance use disorders, organic brain disorders) or medical conditions (brain tumors, cerebral infarction, impaired consciousness, or traumatic brain injury) known to significantly affect EEG signals 3. Individuals currently undergoing treatments expected to significantly alter EEG results (e.g., ECT, TMS, or use of anti-epileptic medications) 4. Any other individuals determined by the principal investigator or sub-investigator to be unsuitable for the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| - Resting-state EEG signals (eyes-open and eyes-closed conditions). - EEG signals during Cognitive Behavioral Therapy (CBT) sessions, Exposure and Response Prevention (ERP). - For the healthy control group: EEG signals during sessions involving instructions or physical activities similar to those provided to the patient group. - Y-BOCS), or HAM-D/HAM-A and RRS | — |
Secondary
| Measure | Time frame |
|---|---|
| - Primary Diagnosis and Comorbidities - Session markers and subjective symptoms during EEG recording - Demographics (Gender, Age, Occupation, etc.) | — |
Countries
Japan
Contacts
Public ContactTaishiro Kishimoto
Keio University School of Medicine Center for the Promotion of Interdisciplinary Research in Medicine and Life Science (PIRMS)
Outcome results
None listed